These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9226103)

  • 21. Hepatic oxygen exchange and energy metabolism in hyperdynamic porcine endotoxemia: effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX30.
    Träger K; Matejovic M; Vogt J; Zülke C; Vlatten A; Wachter U; Altherr J; Brinkmann A; Brückner UB; Jauch KW; Georgieff M; Radermacher P
    Intensive Care Med; 2001 Feb; 27(2):416-25. PubMed ID: 11396287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models.
    Roux SP; Sakariassen KS; Turitto VT; Baumgartner HR
    Arterioscler Thromb; 1991; 11(5):1182-91. PubMed ID: 1911705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs.
    Maalej N; Osman HE; Shanmuganayagam D; Shebuski RJ; Folts JD
    J Cardiovasc Pharmacol; 2005 May; 45(5):389-95. PubMed ID: 15821433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional vascular responses to thromboxane A2 analogue and their blockade with vapiprost, a selective thromboxane receptor blocking drug, in anesthetized dogs.
    Noguchi K; Ojiri Y; Chibana T; Matsuzaki T; Sakanashi M
    Jpn J Pharmacol; 1992 Dec; 60(4):341-8. PubMed ID: 1287269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
    Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
    Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
    J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency.
    Bech FR; Cronenwett JL; McDaniel MD; Ogletree ML; Freeman DH
    J Vasc Surg; 1990 Aug; 12(2):119-25. PubMed ID: 2143235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    White BP; Sullivan AT; Lumley P
    Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis.
    Yao SK; Benedict CR; Rosolowsky M; McNatt J; Falinska B; Campbell WB; Buja LM; Willerson JT
    J Mol Cell Cardiol; 1991 Apr; 23(4):473-82. PubMed ID: 1942081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane.
    Kitzen JM; Chi LG; Uprichard AC; Lucchesi BR
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):68-80. PubMed ID: 1696668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
    Umemura K; Kawai H; Ishihara H; Nakashima M
    Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
    De La Cruz JP; Moreno A; Ruiz-Ruiz MI; Sánchez De La Cuesta F
    Thromb Res; 2000 Feb; 97(3):125-31. PubMed ID: 10680643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
    Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation.
    Fukuchi M; Uematsu T; Araki S; Nakashima M
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):550-4. PubMed ID: 1470226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.